Collegium Pharmaceutical Inc  

(Public, NASDAQ:COLL)   Watch this stock  
Find more results for COLL
+0.14 (0.52%)
Mar 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 26.52 - 27.90
52 week 7.37 - 29.90
Open 26.80
Vol / Avg. 853,332.00/640,700.00
Mkt cap 890.84M
P/E     -
Div/yield     -
EPS -2.48
Shares 32.99M
Beta     -
Inst. own 99%
Mar 7, 2018
Q4 2017 Collegium Pharmaceutical Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -161.23% -262.91%
Operating margin -162.90% -264.95%
EBITD margin - -256.38%
Return on average assets -54.06% -50.32%
Return on average equity -69.68% -62.65%
Employees 250 -
CDP Score - -


780 Dedham St Ste 800
CANTON, MA 02021-1417
United States - Map
+1-781-7133699 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Officers and directors

Michael Thomas Heffernan Chairman of the Board, President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Paul Brannelly CPA Chief Financial Officer, Executive Vice President
Age: 42
Bio & Compensation  - Reuters
Joseph J. Ciaffoni Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Douglas R. Carlson Vice President - Corporate Development
Bio & Compensation  - Reuters
Alison B Fleming Vice President of Product Development
Age: 40
Bio & Compensation  - Reuters
Ernest A. Kopecky Ph.D. Vice President - Clinical Development and Head of Neuroscience
Age: 48
Bio & Compensation  - Reuters
Kevin OKeeffe Vice President - Market Access and Trade
Bio & Compensation  - Reuters
Steven Passik Ph.D. Vice President - Scientific Affairs, Education and Policy
Bio & Compensation  - Reuters
Said Saim Ph.D. Vice President of Pharmaceutical Development
Age: 57
Bio & Compensation  - Reuters
John Weet Ph.D. Vice President - Regulatory Affairs and Quality Assurance
Bio & Compensation  - Reuters